Patents by Inventor Dimitrios Bikiaris

Dimitrios Bikiaris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STABLE INJECTABLE PHARMACEUTICAL COMPOSITION OF NEUROKININ 1 RECEPTOR ANTAGONIST AND PROCESS FOR PREPARATION THEREOF
    Publication number: 20150165045
    Abstract: The present invention relates to a controlled release sterile injectable formulation in the form of solution, suspension or sol-gel formulation for intramuscular or subcutaneous administration comprising a therapeutically effective amount of a neurokinin 1 receptor antagonist, in particular Aprepitant or Fosaprepitant or pharmaceutical acceptable salt, derivative or metabolite thereof. It also relates to a process for developing such formulations.
    Type: Application
    Filed: July 6, 2012
    Publication date: June 18, 2015
    Applicant: PHARMATHEN S.A.
    Inventors: Evangelos Karavas, Efthimios Koutris, Dimitrios Bikiaris, Sotiria Chatidou, Amalia Diakidou, Panagiotis Barmpalexis, Louiza Konstanti, Katerina Minioti
  • Pharmaceutical formulation containing an HMG-COA reductase inhibitor and method for the preparation thereof
    Patent number: 8835486
    Abstract: An improved pharmaceutical formulation for oral administration includes a therapeutically effective quantity of an active ingredient and a stabilizer. The active ingredient is Fluvastatin, or pharmaceutically acceptable salts thereof, and the stabilizer is a mixture of Carrageenans. The stabilizer inhibits isomerization, and/or elimination, and/or oxidation and/or recrystallization of the active ingredient.
    Type: Grant
    Filed: May 12, 2006
    Date of Patent: September 16, 2014
    Inventors: Evangelos Karavas, Efthimios Koutris, Elisavet Ioannidou, Eleni Stathaki, Dimitrios Bikiaris
  • Pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof
    Patent number: 8187635
    Abstract: The present invention relates to a pharmaceutical formulation of solid dosage forms comprising a therapeutically effective amount of a pyrrolidone anticonvulsant agent, and in particular Levetiracetam or a pharmaceutical acceptable salt or derivative thereof, in combination with an effective diluent, such as Dibasic Calcium Phosphate, and additional pharmaceutical excipients, and a process for the preparation thereof by wet granulation.
    Type: Grant
    Filed: October 16, 2007
    Date of Patent: May 29, 2012
    Assignee: Pharmathen S.A
    Inventors: Evangelos Karavas, Efthimios Koutris, Dimitrios Bikiaris, Vicky Samara, Ioanna Koutri, Eleni Stathaki
  • Improved pharmaceutical composition containing a selective estrogen receptor modulator and method for the preparation thereof
    Publication number: 20110065751
    Abstract: The present invention relates to a pharmaceutical formulation of solid dosage forms comprising a therapeutically effective amount of a selective estrogen receptor modulator, and especially Raloxifene or a pharmaceutical acceptable salt thereof, in combination with a super disintegrant such as Primojel, and a process for the preparation thereof by wet granulation.
    Type: Application
    Filed: October 16, 2007
    Publication date: March 17, 2011
    Applicant: PHARMATHEN S.A.
    Inventors: Evangelos Karavas, Efthimios Koutris, Dimitrios Bikiaris, Vicky Samara, Anastasia Kalaskani, Eleni Stathaki
  • Pharmaceutical composition containing a pyrrolidone anticonvulsant agent and method for the preparation thereof
    Publication number: 20110033538
    Abstract: The present invention relates to a pharmaceutical formulation of solid dosage forms comprising a therapeutically effective amount of a pyrrolidone anticonvulsant agent, and in particular Levetiracetam or a pharmaceutical acceptable salt or derivative thereof, in combination with an effective diluent, such as Dibasic Calcium Phosphate, and additional pharmaceutical excipients, and a process for the preparation thereof by wet granulation.
    Type: Application
    Filed: October 16, 2007
    Publication date: February 10, 2011
    Applicant: PHARMATHEN S.A.
    Inventors: Evangelos Karavas, Efthimios Koutris, Dimitrios Bikiaris, Vicky Samara, Ioanna Koutri, Eleni Stathaki
  • SUSTAINED-RELEASE PHARMACEUTICAL FORMULATION CONTAINING AN ANTIMUSCARINIC AGENT AND A WETTING AGENT AS WELL AS A PROCESS FOR THE PREPARATION THEREOF
    Publication number: 20100297225
    Abstract: The present invention relates to improved sustained release dosage forms such as tablets and capsules, and in particular to a pharmaceutical formulation for oral administration comprising a therapeutically effective quantity of an antimuscarinic agent, such as Tolterodine or pharmaceutical acceptable salt, derivative, prodrug and metabolite thereof in combination with a wetting agent, such as Sodium Docusate to improve the release of the active ingredient and a method for the preparation thereof.
    Type: Application
    Filed: December 20, 2007
    Publication date: November 25, 2010
    Applicant: PHARMATHEN S.A.
    Inventors: Evangelos Karavas, Efthimios Koutris, Ioanna Koutri, Vicky Samara, Dimitrios Bikiaris
  • Pharmaceutical Formulation containing an HMG-COA Reductase Inhibitor and method for the preparation thereof
    Publication number: 20100196469
    Abstract: The present invention relates to the formulation of solid dosage forms comprising a therapeutically effective amount of an HMG-CoA reductase inhibitor, and especially Atorvastatin or Fluvastatin or salts thereof, in combination with colloidal clay such as Attapulgite, and a process for the preparation thereof by direct compression.
    Type: Application
    Filed: June 25, 2007
    Publication date: August 5, 2010
    Applicant: PHARMATHEN S.A.
    Inventors: Evangelos Karavas, Efthimios Koutris, Elli Ioannidou, Vicky Samara, Dimitrios Bikiaris
  • PHARMACEUTICAL FORMULATION CONTAINING AN HMG-COA REDUCTASE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF
    Publication number: 20100137400
    Abstract: The present invention relates to improved pharmaceutical formulation for oral administration comprising a therapeutically effective quantity of an HMG-CoA reductase inhibitor, and more particularly Fluvastatin, Atorvastatin or salts thereof in combination with a linear sulphated polysaccharide such as Carrageenan and a method for the preparation thereof.
    Type: Application
    Filed: May 12, 2006
    Publication date: June 3, 2010
    Applicant: PHARMATHEN S.A.
    Inventors: Evangelos Karavas, Efthimios Koutris, Elisavet Ioannidou, Eleni Stathaki, Dimitrios Bikiaris
  • Pharmaceutical Composition Containing Hmg-Coa Reductase Inhibitor And Method For The Preparation Thereof
    Publication number: 20080213356
    Abstract: The present invention relates to the formulation of solid dosage forms comprising a therapeutically effective amount of an HMG-CoA reductase inhibitor, and especially Fluvastatin or Atorvastatin or salts thereof, in combination with inorganic silica polymer such as Dimethicone, and a process for the preparation thereof by direct compression.
    Type: Application
    Filed: September 13, 2006
    Publication date: September 4, 2008
    Applicant: PHARMATHEN S.A.
    Inventors: Evangelos Karavas, Eftimios Koutris, Dimitrios Bikiaris